189 related articles for article (PubMed ID: 22222871)
1. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.
Fang X; Zhang S; Sun X; Li J; Sun T
Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats.
Xue X; Yu Z; Jin H; Liang L; Li J; Li X; Wang Y; Cui S; Li G
BMC Vet Res; 2021 Jan; 17(1):36. PubMed ID: 33461549
[TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice.
Zhang M; Ge J; Li X; Chen W; Wang X; Wen Z; Bu Z
Virol J; 2016 Feb; 13():31. PubMed ID: 26911572
[TBL] [Abstract][Full Text] [Related]
4. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
Braxton CL; Puckett SH; Mizel SB; Lyles DS
J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
[TBL] [Abstract][Full Text] [Related]
5. Assessment of a novel recombinant vesicular stomatitis virus with triple mutations in its matrix protein as a vaccine for pigs.
Fang X; Qi B; Ma Y; Zhou X; Zhang S; Sun T
Vaccine; 2015 Nov; 33(46):6268-76. PubMed ID: 26431989
[TBL] [Abstract][Full Text] [Related]
6. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
Publicover J; Ramsburg E; Rose JK
J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
[TBL] [Abstract][Full Text] [Related]
7. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.
Ma Y; Wei Y; Zhang X; Zhang Y; Cai H; Zhu Y; Shilo K; Oglesbee M; Krakowka S; Whelan SP; Li J
J Virol; 2014 Mar; 88(5):2913-26. PubMed ID: 24371058
[TBL] [Abstract][Full Text] [Related]
8. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
9. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
[TBL] [Abstract][Full Text] [Related]
10. Rhabdovirus-based vaccine platforms against henipaviruses.
Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
[TBL] [Abstract][Full Text] [Related]
11. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
Lee SS; Phy K; Peden K; Sheng-Fowler L
Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
[TBL] [Abstract][Full Text] [Related]
12. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Kapadia SU; Simon ID; Rose JK
Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
[TBL] [Abstract][Full Text] [Related]
13. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins.
Munis AM; Tijani M; Hassall M; Mattiuzzo G; Collins MK; Takeuchi Y
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232190
[TBL] [Abstract][Full Text] [Related]
15. Porcine monocyte-derived dendritic cells can be differentially activated by vesicular stomatitis virus and its matrix protein mutants.
Sun G; Fang X; Wu H; Zhou X; Ke Y; Sun T
Vet Microbiol; 2018 Jun; 219():30-39. PubMed ID: 29778202
[TBL] [Abstract][Full Text] [Related]
16. Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha.
Publicover J; Ramsburg E; Robek M; Rose JK
J Virol; 2006 Jul; 80(14):7028-36. PubMed ID: 16809308
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.
Roberts A; Kretzschmar E; Perkins AS; Forman J; Price R; Buonocore L; Kawaoka Y; Rose JK
J Virol; 1998 Jun; 72(6):4704-11. PubMed ID: 9573234
[TBL] [Abstract][Full Text] [Related]
18. Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene.
Choi JA; Wu K; Kim GN; Saeedian N; Seon SH; Park G; Jung DI; Jeong HW; Kim NH; Seo SH; Lee S; Song M; Kang CY
J Gen Virol; 2021 Apr; 102(4):. PubMed ID: 33913804
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
